2024
Accelerating Medicines Partnership® Schizophrenia (AMP® SCZ): Rationale and Study Design of the Largest Global Prospective Cohort Study of Clinical High Risk for Psychosis
Wannan C, Nelson B, Addington J, Allott K, Anticevic A, Arango C, Baker J, Bearden C, Billah T, Bouix S, Broome M, Buccilli K, Cadenhead K, Calkins M, Cannon T, Cecci G, Chen E, Cho K, Choi J, Clark S, Coleman M, Conus P, Corcoran C, Cornblatt B, Diaz-Caneja C, Dwyer D, Ebdrup B, Ellman L, Fusar-Poli P, Galindo L, Gaspar P, Gerber C, Glenthøj L, Glynn R, Harms M, Horton L, Kahn R, Kambeitz J, Kambeitz-Ilankovic L, Kane J, Kapur T, Keshavan M, Kim S, Koutsouleris N, Kubicki M, Kwon J, Langbein K, Lewandowski K, Light G, Mamah D, Marcy P, Mathalon D, McGorry P, Mittal V, Nordentoft M, Nunez A, Pasternak O, Pearlson G, Perez J, Perkins D, Powers A, Roalf D, Sabb F, Schiffman J, Shah J, Smesny S, Spark J, Stone W, Strauss G, Tamayo Z, Torous J, Upthegrove R, Vangel M, Verma S, Wang J, Rossum I, Wolf D, Wolff P, Wood S, Yung A, Agurto C, Alvarez-Jimenez M, Amminger P, Armando M, Asgari-Targhi A, Cahill J, Carrión R, Castro E, Cetin-Karayumak S, Chakravarty M, Cho Y, Cotter D, D’Alfonso S, Ennis M, Fadnavis S, Fonteneau C, Gao C, Gupta T, Gur R, Gur R, Hamilton H, Hoftman G, Jacobs G, Jarcho J, Ji J, Kohler C, Lalousis P, Lavoie S, Lepage M, Liebenthal E, Mervis J, Murty V, Nicholas S, Ning L, Penzel N, Poldrack R, Polosecki P, Pratt D, Rabin R, Eichi H, Rathi Y, Reichenberg A, Reinen J, Rogers J, Ruiz-Yu B, Scott I, Seitz-Holland J, Srihari V, Srivastava A, Thompson A, Turetsky B, Walsh B, Whitford T, Wigman J, Yao B, Yuen H, Ahmed U, Byun A, Chung Y, Do K, Hendricks L, Huynh K, Jeffries C, Lane E, Langholm C, Lin E, Mantua V, Santorelli G, Ruparel K, Zoupou E, Adasme T, Addamo L, Adery L, Ali M, Auther A, Aversa S, Baek S, Bates K, Bathery A, Bayer J, Beedham R, Bilgrami Z, Birch S, Bonoldi I, Borders O, Borgatti R, Brown L, Bruna A, Carrington H, Castillo-Passi R, Chen J, Cheng N, Ching A, Clifford C, Colton B, Contreras P, Corral S, Damiani S, Done M, Estradé A, Etuka B, Formica M, Furlan R, Geljic M, Germano C, Getachew R, Goncalves M, Haidar A, Hartmann J, Jo A, John O, Kerins S, Kerr M, Kesselring I, Kim H, Kim N, Kinney K, Krcmar M, Kotler E, Lafanechere M, Lee C, Llerena J, Markiewicz C, Matnejl P, Maturana A, Mavambu A, Mayol-Troncoso R, McDonnell A, McGowan A, McLaughlin D, McIlhenny R, McQueen B, Mebrahtu Y, Mensi M, Hui C, Suen Y, Wong S, Morrell N, Omar M, Partridge A, Phassouliotis C, Pichiecchio A, Politi P, Porter C, Provenzani U, Prunier N, Raj J, Ray S, Rayner V, Reyes M, Reynolds K, Rush S, Salinas C, Shetty J, Snowball C, Tod S, Turra-Fariña G, Valle D, Veale S, Whitson S, Wickham A, Youn S, Zamorano F, Zavaglia E, Zinberg J, Woods S, Shenton M. Accelerating Medicines Partnership® Schizophrenia (AMP® SCZ): Rationale and Study Design of the Largest Global Prospective Cohort Study of Clinical High Risk for Psychosis. Schizophrenia Bulletin 2024, 50: 496-512. PMID: 38451304, PMCID: PMC11059785, DOI: 10.1093/schbul/sbae011.Peer-Reviewed Original ResearchClinical high-risk individualsClinical high riskNational Institute of Mental HealthInstitute of Mental HealthAttenuated positive symptomsPersistent negative symptomsTransition to psychosisCHR statusHigh riskNegative symptomsPositive symptomsAnxiety symptomsPsychosocial functioningCognitive dataOutcomes of individualsDigital health technologiesDaily surveysPsychosisSCZPublic health needsMental healthNovel pharmacological interventionsSchizophreniaClinical outcomesHealth needs
2023
Effects of exercise intervention on psychotic symptoms: A meta-analysis and hypothetical model of neurobiological mechanisms
Oliva H, Monteiro-Junior R, Oliva I, Powers A. Effects of exercise intervention on psychotic symptoms: A meta-analysis and hypothetical model of neurobiological mechanisms. Progress In Neuro-Psychopharmacology And Biological Psychiatry 2023, 125: 110771. PMID: 37075881, DOI: 10.1016/j.pnpbp.2023.110771.Peer-Reviewed Original ResearchConceptsExercise interventionGeneral symptomsPsychotic symptomsEfficacy of exerciseEffects of exerciseSpecific brain areasWeb of ScienceCochrane CENTRALSymptom improvementTemporal lobeBrain areasLarge effect sizesPsychotic patientsPositive symptomsNegative symptomsSymptomsNeurobiological mechanismsNeurophysiology studiesInterventionExerciseEffect sizeDatabase searchSignificant improvementNeurobiological modelsPatientsSampling from different populations: Sociodemographic, clinical, and functional differences between samples of first episode psychosis individuals and clinical high-risk individuals who progressed to psychosis
Hagler M, Ferrara M, Yoviene Sykes L, Li F, Addington J, Bearden C, Cadenhead K, Cannon T, Cornblatt B, Perkins D, Mathalon D, Seidman L, Tsuang M, Walker E, Powers A, Allen A, Srihari V, Woods S. Sampling from different populations: Sociodemographic, clinical, and functional differences between samples of first episode psychosis individuals and clinical high-risk individuals who progressed to psychosis. Schizophrenia Research 2023, 255: 239-245. PMID: 37028205, PMCID: PMC10207144, DOI: 10.1016/j.schres.2023.03.047.Peer-Reviewed Original ResearchConceptsFirst-episode psychosis servicesClinical high riskClinical high-risk individualsEarly detectionFirst-episode psychosis individualsRecent psychiatric hospitalizationCourse of illnessHigh-risk individualsAttenuated positive symptomsCHR researchGeographic catchmentSyndromal psychosisPsychosis individualsPsychiatric hospitalizationEarly intervention effortsHigh riskPsychosis servicesPositive symptomsGlobal functioningClinical resourcesProtective factorsDifferent populationsFE participantsGeneralizability of findingsFES program
2022
Three prominent self-report risk measures show unique and overlapping utility in characterizing those at clinical high-risk for psychosis
Williams TF, Powers AR, Ellman LM, Corlett PR, Strauss GP, Schiffman J, Waltz JA, Silverstein SM, Woods SW, Walker EF, Gold JM, Mittal VA. Three prominent self-report risk measures show unique and overlapping utility in characterizing those at clinical high-risk for psychosis. Schizophrenia Research 2022, 244: 58-65. PMID: 35597134, PMCID: PMC9829103, DOI: 10.1016/j.schres.2022.05.006.Peer-Reviewed Original ResearchConceptsProdromal Questionnaire-BriefPositive symptomsSelf-report questionnairesSpecific positive symptomsStructured Clinical InterviewClinical high riskCriterion validityHealthy controlsSpecific symptomsHigh riskDiscriminant validityPsychosis symptomsClinical InterviewCHR individualsStrong convergent validitySymptomsPsychosis riskNeuropsychological testsConsistent significant correlationLimited specificitySignificant correlationConvergent validityPsychosisConstruct validityQuestionnaire
2021
Computational Mechanism for the Effect of Psychosis Community Treatment: A Conceptual Review From Neurobiology to Social Interaction
Benrimoh D, Sheldon A, Sibarium E, Powers AR. Computational Mechanism for the Effect of Psychosis Community Treatment: A Conceptual Review From Neurobiology to Social Interaction. Frontiers In Psychiatry 2021, 12: 685390. PMID: 34385938, PMCID: PMC8353084, DOI: 10.3389/fpsyt.2021.685390.Peer-Reviewed Original ResearchComputational modelAssertive community treatmentProcessing-based accountExperience of psychosisEvidence-based clinical interventionsCommunity treatmentPrevious computational modelsCognitive resourcesPositive psychotic symptomsComputational underpinningsComputational mechanismsSocial interactionStrong social elementSensory informationPositive symptomsConceptual reviewClinical interventionsEarly psychosisSocial elementsCandidate mechanismPsychotic symptomsNeurobiologyPsychosisConceptual paperMultiple levels